Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese
- PDF / 870,823 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 34 Downloads / 201 Views
PHARMACOKINETICS AND DISPOSITION
Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia Wenqian Chen 1 & Huifang Liu 1 & Qianlin Wang 2 & Xiaoxing Wang 1 & Xudong Kong 1 & Xiaoxue Wang 1 & Xianglin Zhang 1 & Qingyuan Zhan 2 & Pengmei Li 1 Received: 26 May 2020 / Accepted: 27 August 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Aims The efficacy and toxicity of polymyxin B (PB) are closely related to its pharmacokinetic/pharmacodynamic (PK/PD) index area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) ratio. The purpose of this study was to obtain PK data for PB in Chinese severe pneumonia patients and establish appropriate blood sampling time points for the PB therapeutic drug monitoring (TDM). Subject and method After treatment with at least four doses of PB (50 IU, q12h), the blood samples were collected immediately after the end of infusion (C0) and 1.5, 2, 4, 6, 8, and 12 h (C1.5, C2, C4, C6, C8, C12) after PB administration. The PB blood plasma concentrations were determined using an ultra-performance liquid chromatography–tandem mass spectrometer (UPLC-MS/MS). All 42 patients were randomly divided into modeling (n = 24) and validation (n = 18) groups. The relationship between AUCss,24h and PB plasma concentration at each time point in modeling group was analyzed using limited sampling strategy and a PK method based on one-compartment with correction model. Results C6 scheme was found to provide the most accurate prediction of AUCss,24h values (r2 = 0.984) with the target value of 1.9–4.2 μg/ml at steady state to reach the 50–100 μg h/ml criteria of AUCss,24h. C0 with target value of 1.0–2.8 μg/ml can be considered an alternative sampling scheme (r2 = 0.900) but prediction deviation may exist. C0 and Cmax sampling scheme also demonstrated good predicting ability of AUC values using PK model. Conclusion This study provides a clear plan for the implementation of TDM of PB, which is useful for optimizing the dosing regimen and individualizing treatment in severe pneumonia patients. Keywords Polymyxin B . Limited sampling strategy . Therapeutic drug monitoring . AUC . Pharmacokinetics
Introduction Polymyxins are a group of non-ribosomal polypeptide antibiotics that have been gradually replaced by new antibacterial drugs due to polymyxin’s narrow antibacterial spectrum and Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00228-020-02986-x) contains supplementary material, which is available to authorized users. * Pengmei Li [email protected] 1
Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China
2
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China
undesirable side effects. However, under pressure of growing infection rates of multidrug-resistant gram-negative bacteria, polymyxin has gained increased attention as the last li
Data Loading...
